{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:57:38Z","timestamp":1794009458672,"version":"4.8.0"},"reference-count":35,"publisher":"American Society for Clinical Investigation","issue":"7","funder":[{"name":"ContraFect","award":["ContraFect"],"award-info":[{"award-number":["ContraFect"]}],"id":[{"id":"https:\/\/ror.org\/02dr28080","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,8]]},"DOI":"10.1172\/jci136577","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T12:00:49Z","timestamp":1586433649000},"page":"3750-3760","source":"Crossref","is-referenced-by-count":133,"title":["Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis"],"prefix":"10.1172","volume":"130","author":[{"suffix":"Jr.","given":"Vance G.","family":"Fowler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita F.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Lipka-Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-573X","authenticated-orcid":false,"given":"Raymond","family":"Schuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Pomerantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8623-5999","authenticated-orcid":false,"given":"Luis","family":"J\u00e1uregui-Peredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Ralph","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Zervos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Cassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.17.2066"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1086\/379321"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1086\/345476"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01157-10"},{"key":"B5"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz112"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00134-14"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0147-4"},{"issue":"7","key":"B9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02666-16","article-title":"Bacteriophage lysin CF-301, a potent antistaphylococcal biofilm agent","volume":"61","author":"Schuch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"B10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02291-18","article-title":"The antistaphylococcal lysin, CF-301, activates key host factors in human blood to potentiate methicillin-resistant Staphylococcus aureus bacteriolysis","volume":"63","author":"Indiani","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit637"},{"issue":"2","key":"B12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01885-19","article-title":"Exebacase demonstrates in vitro synergy with a broad range of antibiotics against both methicillin-resistant and methicillin-susceptible Staphylococcus aureus","volume":"64","author":"Watson","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"B13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01078-19","article-title":"Antimicrobial activity of exebacase (lysin CF-301) against the most common causes of infective endocarditis","volume":"63","author":"Watson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.114879"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6809e1"},{"key":"B16","unstructured":"CDC. Antibiotic resistance threats in the United States, 2019. https:\/\/www.cdc.gov\/drugresistance\/Biggest-Threats Accessed April 27, 2020"},{"key":"B17"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"B19","unstructured":"A phase 3 telavancin Staphylococcus aureus (S. aureus) bacteremia trial. https:\/\/clinicaltrials.gov NCT02208063. Accessed April 27, 2020"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy774"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00096-06"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00570-07"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-3081"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.495115"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1086\/597031"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32456-X"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.0103"},{"issue":"5","key":"B28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B29","first-page":"S150","article-title":"Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"51 suppl 1","author":"Infectious Diseases Society of America","year":"2010","journal-title":"Clin Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1755-5"},{"key":"B31","unstructured":"U.S. Food and Drug Administration. FDA Guidance Documents. Center for Drug Evaluation and Research. Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment.  https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia-developing-drugs. Updated August 24, 2018. Accessed April 27, 2020"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21724-z"},{"issue":"6","key":"B33","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02616-18","article-title":"Postantibiotic and sub-MIC effects of exebacase (lysin CF-301) enhance antimicrobial activity against Staphylococcus aureus","volume":"63","author":"Oh","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2009.05.020"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000296"}],"container-title":["Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jci.org\/articles\/view\/136577\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T13:34:57Z","timestamp":1691069697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jci.org\/articles\/view\/136577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7,1]]},"published-print":{"date-parts":[[2020,7,1]]}},"alternative-id":["10.1172\/JCI136577"],"URL":"https:\/\/doi.org\/10.1172\/jci136577","relation":{},"ISSN":["0021-9738","1558-8238"],"issn-type":[{"value":"0021-9738","type":"print"},{"value":"1558-8238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]}}}